Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Kirn serves as President, Chief Executive Officer and Director of 4D Molecular Therapeutics. His biographical information is set forth in the proxy statement's director election proposal.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies

Structured records are unavailable. This does not establish that no records exist.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

4D Molecular Therapeutics, Inc.

2013-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

4D Molecular Therapeutics, Inc.

Open 4D Molecular Therapeutics, Inc. profile →

Director at 4D Molecular Therapeutics, Inc.

2013-01-01 → End not stated

current · source reported

Observed: 2026-09-24

4D Molecular Thera…4D Molecular Therapeutics, Inc.David Kirn, M.D.

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingFDMT DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:david-kirn-m-d
Record version
public-0

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. FDMT DEF 14A executive officers

    sec filing · Source published: Apr 28, 2026 · Retrieved: May 4, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 4, 2026
    • Executive company: Executive at 4D Molecular Therapeutics, Inc. · Claim reviewed: May 4, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: May 4, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 4, 2026

  2. Open source

    sec proxy · Source published: Apr 28, 2026 · Retrieved: Sep 1, 2026

    Supports 1 claim
    • Professional Role: Director at 4D Molecular Therapeutics, Inc. · Claim reviewed: May 4, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of 4D Molecular Therapeutics, Inc. · Claim reviewed: May 4, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Board membership · Source reportedServes on the board of 4D Molecular Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at 4D Molecular Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive title · Source reportedExecutive title: President, Chief Executive Officer and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Sep 1, 2026

    Supports: Director at 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)

  3. https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership